[The assessment of a role of muramyl peptides in the treatment of patients with aggressive form of periodontitis].

Izuchenie roli kompozitsii muramilpeptidov pri lechenii patsientov s agressivnoi formoi parodontita.
Porphyromonas gingivalis human neutrophil peptides muramyl peptides periodontitis α-defensins

Journal

Stomatologiia
ISSN: 0039-1735
Titre abrégé: Stomatologiia (Mosk)
Pays: Russia (Federation)
ID NLM: 0412072

Informations de publication

Date de publication:
2022
Historique:
entrez: 31 5 2022
pubmed: 1 6 2022
medline: 3 6 2022
Statut: ppublish

Résumé

Was to determine the effect of the drug based on the composition of muramyl peptides isolated from the cell walls of gram-negative bacteria on the production of α-defensins and the detectability of 60 patients aged 28 to 40 years with an aggressive form of periodontitis were randomized into two equal groups, the main and control. In both groups, patients were removed dental deposits and taught the rules of oral hygiene, followed by three-fold control. In the main group, 200 micrograms of the drug based on the composition of muramyl peptides were additionally administered intramuscularly daily for 7 days. Initially and after 7, 21, 90 days, the level of human neutrophil peptides (hnp In patients of the control group, the concentration of hnp The drug based on the composition of muramyl peptides of the cell wall of gram-negative bacteria potentiates the eradication of P. gingivalis by stimulating the production of hnp Определение влияния препарата на основе композиции мурамилпептидов, выделенных из клеточных стенок грамотрицательных бактерий, на выработку α-дефензинов и выявляемость 60 пациентов в возрасте от 28 до 40 лет с агрессивной формой пародонтита рандомизированы в две равные группы, основную и контрольную. В обеих группах пациентам снимали зубные отложения и обучали правилам гигиены рта с последующим трехкратным контролем. В основной группе дополнительно пациентам ежедневно внутримышечно вводили по 200 мкг препарата на основе композиции мурамилпептидов в течение 7 дней. Исходно и через 7, 21, 90 дней определяли уровень человеческих нейтрофильных пептидов (HNP У пациентов группы контроля концентрация HNP Препарат на основе композиции мурамилпептидов клеточной стенки грамотрицательных бактерий потенцирует эрадикацию

Autres résumés

Type: Publisher (rus)
Определение влияния препарата на основе композиции мурамилпептидов, выделенных из клеточных стенок грамотрицательных бактерий, на выработку α-дефензинов и выявляемость

Identifiants

pubmed: 35640175
doi: 10.17116/stomat202210103122
doi:

Substances chimiques

Peptides 0

Types de publication

Journal Article Randomized Controlled Trial

Langues

rus

Sous-ensembles de citation

IM

Pagination

22-26

Auteurs

A I Grudyanov (AI)

Central Research Institute of Dentistry and Maxillofacial Surgery of the Ministry of Health of the Russian Federation, Moscow, Russia.

E V Fomenko (EV)

Central Research Institute of Dentistry and Maxillofacial Surgery of the Ministry of Health of the Russian Federation, Moscow, Russia.

E P Bistritskaya (EP)

Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia.

C D Ahmad El-Abed (CD)

Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia.

O A Svitich (OA)

Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia.
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.

O V Kalyuzhin (OV)

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH